The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Chimeric antigen receptor (CAR) T cells have achieved true clinical success in treating
hematological malignancy patients, laying the foundation of CAR T cells as a new pillar of …

Chimeric antigen receptor (CAR) costimulatory domains derived from native immune
receptors steer the phenotypic output of therapeutic T cells. We constructed a library of …

Cell therapies are powerful technologies in which human cells are reprogrammed for
therapeutic applications such as killing cancer cells or replacing defective cells. The …

The functional state of chimeric antigen receptor T (CAR T) cells determines their efficacy in
vivo. Exhausted CAR T cells exhibit decreased proliferative capacity, impaired anti-tumor …

Cell and gene therapies hold tremendous promise for treating a range of difficult-to-treat
diseases. However, concerns over the safety and efficacy require to be further addressed in …

Chimeric antigen receptor (CAR)-T cells are powerful therapeutics; however, their efficacy is
often hindered by critical hurdles. Here utilizing the endocytic feature of the cytotoxic T …

Synthetic biology (synbio) tools, such as chimeric antigen receptors (CARs), have been
designed to target, activate, and improve immune cell responses to tumors. These therapies …

The use of a patient's own immune or tumor cells, manipulated ex vivo, enables Ag-or
patient-specific immunotherapy. Despite some clinical successes, there remain significant …

The immune system includes an array of specialized cells that keep us healthy by
responding to pathogenic cues. Investigations into the mechanisms behind immune cell …